PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10826644

Patterning multiple antibodies on polystyrene.

R A Brizzolara
View original source ↗Export metadata ↓

Abstract

A method for patterning different antibodies on polystyrene is described. The polystyrene surface is coated with a material resistant to antibody adsorption and the coating material is selectively removed from the region where antibody adsorption is desired, exposing clean polystyrene. Upon immersion of the substrate in antibody solution, antibodies adsorb to the clean polystyrene, but not to the coated areas of the surface. Two methods have been used to remove the coating: ion beam sputtering and mechanical etching. The pattern was verified using gold-labeled antigen in conjunction with X-ray photoelectron spectroscopy and with FITC-labeled antigen and fluorescence microscopy. Substrates patterned in this way could be used in conjunction with a charge-coupled detector for a multi-analyte biosensor. This patterning technique is suitable for applications in which a fast, inexpensive fabrication process is necessary, for example, in single-use sensors.

Explore related subjects

AntibodiesBiosensing TechniquesPolystyrenesJournal ArticleResearch Support, U.S. Gov't, Non-P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R A Brizzolara. 2000. Patterning multiple antibodies on polystyrene.. https://doi.org/10.1016/s0956-5663(99)00070-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies↗
PubMed2001

Protein affinity maturation in vivo using E. coli mutator cells.

This protocol provides a simple in vivo strategy for introducing random mutations to a target DNA sequences using E. coli mutator cells. The method has been used in our laboratory for affinity maturation of proteins encoded by target DNA sequences. Selection conditions can be modified for antibody fragments with increased production levels. Growth conditions in E. coli mutator cells can be adjusted to introduce a single random point mutation per kilobase of DNA, approximately equivalent to one codon change per scFv fragment.

Antibodies↗
PubMed2001

Anti-Ri-associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma.

BACKGROUND: There are several case reports describing paraneoplastic syndromes in patients with various forms of bladder carcinoma. Current immunologic analyses have enabled the identification of the antineuronal autoantibodies associated with specific syndromes. METHODS: A patient with a history of bladder carcinoma presented with opsoclonus and myoclonus. RESULTS: Workup confirmed the presence of anti-Ri antibodies in the patient's serum and cerebrospinal fluid. The target Ri antigen was found to be expressed by the tumor. CONCLUSIONS: To the authors' knowledge, there are few reports in the literature describing the long-term clinical follow-up and postmortem evaluation in a patient with this form of paraneoplastic syndrome. More important, the authors believe the current study represents the first time that the presence of anti-Ri antibodies has been noted in a paraneoplastic syndrome associated with transitional cell carcinoma of the bladder.

Antibodies↗